Thyroid gland and cerebella lesions: New risk factors for sudden cardiac death in schizophrenia?


Autoria(s): SCORZA, Fulvio A.; CAVALHEIRO, Esper A.; ALBUQUERQUE, Marly de; ALBUQUERQUE, Juliana de; CYSNEIROS, Roberta M.; TERRA, Vera C.; ARIDA, Ricardo M.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2011

Resumo

People with schizophrenia show a two to threefold increased risk to die prematurely than those without schizophrenia. Patients` life style, suicide, premature development of cardiovascular disease, high prevalence of metabolic syndrome and sudden cardiac death are well-known causes of the excess mortality. The exact pathophysiological cause of sudden death in schizophrenia is unknown, but it is likely that cardiac arrhythmia and respiratory abnormalities play potential role. Some antipsychotics may be associated with cardiovascular adverse events (e.g., QT interval prolongation) and lesions in specific brain regions, such as cerebella may be associated with respiratory abnormalities, suggesting that metabolic and brain dysfunction could lead to sudden cardiac death in patients with schizophrenia. However, exact knowledge regarding the association of these findings and schizophrenia is lacking. As subclinical hyperthyroidism has been linked with increased risk of cardiovascular disease and cerebella progressive atrophy has been observed in patients with schizophrenia, we propose in this paper that subclinical thyroid dysfunction and cerebella volume loss could be considered as new risk factor for sudden cardiac death in schizophrenia. (C) 2010 Elsevier Ltd. All rights reserved.

FAPESP

CInAPCe-FAPESP

INCT/MCT

CNPq

Identificador

MEDICAL HYPOTHESES, v.76, n.2, p.251-253, 2011

0306-9877

http://producao.usp.br/handle/BDPI/25141

10.1016/j.mehy.2010.10.012

http://dx.doi.org/10.1016/j.mehy.2010.10.012

Idioma(s)

eng

Publicador

CHURCHILL LIVINGSTONE

Relação

Medical Hypotheses

Direitos

restrictedAccess

Copyright CHURCHILL LIVINGSTONE

Palavras-Chave #ANTIPSYCHOTIC-DRUGS #CARDIOVASCULAR-DISEASE #ATRIAL-FIBRILLATION #METABOLIC SYNDROME #HYPERTHYROIDISM #DYSFUNCTION #ILLNESS #Medicine, Research & Experimental
Tipo

article

original article

publishedVersion